"サノフィ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonSanofi's lunsekimig scores dual mid-stage wins in respiratory trials, stumbles in dermatitis - Fi...
Sanofi's lunsekimig scores dual mid-stage wins in respiratory trials, stumbles in dermatitis FirstWord Pharma
Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study - Fierce Biotech
Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study Fierce Biotech
Sanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczema - Endpoints News
Sanofi bispecific sails through asthma, sinusitis trials, but disappoints in eczema Endpoints News
Sanofi immune drug hopeful posts mixed results in mid-stage tests - BioPharma Dive
Sanofi immune drug hopeful posts mixed results in mid-stage tests BioPharma Dive
With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine -...
With Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engine Fierce Pharma
Sanofi's bispecific lunsekimig has mixed readouts in phase 2 - pharmaphorum
Sanofi's bispecific lunsekimig has mixed readouts in phase 2 pharmaphorum
Sanofi’s bispecific scores in respiratory diseases but fails in eczema - Clinical Trials Arena
Sanofi’s bispecific scores in respiratory diseases but fails in eczema Clinical Trials Arena
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off - BioSpace
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off BioSpace
Sanofi’s lunsekimig delivers in asthma but stumbles in dermatitis - The Pharma Letter
Sanofi’s lunsekimig delivers in asthma but stumbles in dermatitis The Pharma Letter
Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents - Yah...
Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents Yahoo Finance
Four Penn State researchers receive iDEA-TECH awards from Sanofi - Penn State Health News
Four Penn State researchers receive iDEA-TECH awards from Sanofi Penn State Health News
Sanofi’s Lunsekimig Delivers In Respiratory Phase II Studies, Misses In Dermatitis - Citeline New...
Sanofi’s Lunsekimig Delivers In Respiratory Phase II Studies, Misses In Dermatitis Citeline News & Insights
The Fast (And Intense) Lane: How Expedited Approvals Are Going Further and Faster for Patients - ...
The Fast (And Intense) Lane: How Expedited Approvals Are Going Further and Faster for Patients Sanofi
Sanofi’s lunsekimig hits primary and key secondary endpoints in phase 2 Asthma and CRSwNP trials ...
Sanofi’s lunsekimig hits primary and key secondary endpoints in phase 2 Asthma and CRSwNP trials (SNY:NASDAQ) Seeking Alpha
Sanofi launches innovation and operation centre in China - Reuters
Sanofi launches innovation and operation centre in China Reuters
Sanofi Steps Up Autoimmune Push with Up-to-$1.23B+ Kali Collaboration - Genetic Engineering and B...
Sanofi Steps Up Autoimmune Push with Up-to-$1.23B+ Kali Collaboration Genetic Engineering and Biotechnology News
$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Su...
Sanofi eczema drug weighed down by mixed results, safety concerns - BioPharma Dive
Sanofi eczema drug weighed down by mixed results, safety concerns BioPharma Dive
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design - BioSpace
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design BioSpace
A Million Conversations: Bridging Trust Gap - Sanofi
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Reuters
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment Reuters
Kakao Healthcare, Sanofi launch AI-driven RWE studies in Korea - koreabiomed.com
Kakao Healthcare, Sanofi launch AI-driven RWE studies in Korea koreabiomed.com
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+ - BioSpace
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+ BioSpace
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease - Yahoo Finance
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease Yahoo Finance
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific - Fierce...
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific Fierce Biotech
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions - Reuters
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions Reuters
Sanofi R&D Updates Highlight Venglustat Win And In Vivo CAR-T Potential - Yahoo Finance
Sanofi R&D Updates Highlight Venglustat Win And In Vivo CAR-T Potential Yahoo Finance
Rare Blood Disorders - Sanofi
Rare Blood Disorders Sanofi
Paul Hudson out as Sanofi CEO - statnews.com
Paul Hudson out as Sanofi CEO statnews.com
COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmi...
NANOBODY® Technology Platform - Sanofi
Sanofi: Information concerning the total number of voting rights and shares - February 2026 - Yah...
Sanofi: Information concerning the total number of voting rights and shares - February 2026 Yahoo Finance
Sanofi worker’s grievance dismissed after signing severance release - HR Law Canada
Sanofi worker’s grievance dismissed after signing severance release HR Law Canada
AlphaValue/Baader Europe Lowers Target Price, Estimates for Sanofi Amid R&D Setbacks - marketscre...
AlphaValue/Baader Europe Lowers Target Price, Estimates for Sanofi Amid R&D Setbacks marketscreener.com
Sanofi scraps plan to develop next-generation mRNA seasonal flu vaccine - CIDRAP
Sanofi scraps plan to develop next-generation mRNA seasonal flu vaccine CIDRAP
As its immunology work draws attention, Sanofi also pushes forward in rare disease - statnews.com
As its immunology work draws attention, Sanofi also pushes forward in rare disease statnews.com
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence - BioSpace
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence BioSpace
SANOFI : Jefferies reiterates its Buy rating - marketscreener.com
SANOFI : Jefferies reiterates its Buy rating marketscreener.com
German CDMO Adragos buys French sterile injectables plant from Sanofi - Fierce Pharma
German CDMO Adragos buys French sterile injectables plant from Sanofi Fierce Pharma
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker - Benzinga
From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker Benzinga
Amgen and Sanofi end epic battle over Praluent and Repatha - JUVE Patent
Amgen and Sanofi end epic battle over Praluent and Repatha JUVE Patent
Sanofi CEO: The enterprise AI shift will reshape pharma in 2026 - Fortune
Sanofi CEO: The enterprise AI shift will reshape pharma in 2026 Fortune
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals - BioSpace
Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals BioSpace
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo - B...
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo BioSpace
Sanofi reports positive data in two respiratory diseases - marketscreener.com
Sanofi reports positive data in two respiratory diseases marketscreener.com
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo - BioPharma Dive
Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo BioPharma Dive
Sanofi Deepens Mirecule And Earendil Ties To Shape Rare Disease Future - Yahoo Finance
Sanofi Deepens Mirecule And Earendil Ties To Shape Rare Disease Future Yahoo Finance
Sanofi vaccine sales face headwinds from US policy shifts - Reuters
Sanofi vaccine sales face headwinds from US policy shifts Reuters
AlphaValue turns less bullish on Sanofi - marketscreener.com
AlphaValue turns less bullish on Sanofi marketscreener.com
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor - F...
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor Fierce Biotech
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln - Reuters
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln Reuters
Kakao Healthcare and Sanofi Partner on AI Healthcare - Let's Data Science
Kakao Healthcare and Sanofi Partner on AI Healthcare Let's Data Science
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer - Reuters
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer Reuters
Sanofi announces leadership evolution in Specialty Care Business Unit - Yahoo Finance
Sanofi announces leadership evolution in Specialty Care Business Unit Yahoo Finance
Sanofi's tolebrutinib woes pile up with FDA delay, trial miss - Fierce Biotech
Sanofi's tolebrutinib woes pile up with FDA delay, trial miss Fierce Biotech
Spurned by Sanofi, Orano turns to Roche | ApexOnco - Clinical Trials news and analysis - Oncology...
Spurned by Sanofi, Orano turns to Roche | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Sanofi records win and loss with rare disease drug in Phase III trials - Clinical Trials Arena
Sanofi records win and loss with rare disease drug in Phase III trials Clinical Trials Arena
JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns - Fierce B...
JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns Fierce Biotech
Sanofi becomes latest pharma to hold fire on UK R&D investments as funding fallout continues - Fi...
Sanofi becomes latest pharma to hold fire on UK R&D investments as funding fallout continues Fierce Biotech
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine - Fierce Biotech
Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine Fierce Biotech
Sanofi's genetic disorder drug shows mixed results in late-stage trials - Reuters
Sanofi's genetic disorder drug shows mixed results in late-stage trials Reuters
Like Sanofi, German Merck keeps the CEACAM5 faith | ApexOnco - Clinical Trials news and analysis ...
Like Sanofi, German Merck keeps the CEACAM5 faith | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal - CNBC
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal CNBC
Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees - Reuters
Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees Reuters
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’ - BioPharma Dive
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’ BioPharma Dive
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an i...
Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Yahoo Finance
Sanofi's new CEO needs to fix drug pipeline and navigate Trump - Reuters
Sanofi's new CEO needs to fix drug pipeline and navigate Trump Reuters
Sanofi steps back from radioconjugates | ApexOnco - Clinical Trials news and analysis - Oncology ...
Sanofi steps back from radioconjugates | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Yahoo Finance
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 Yahoo Finance
Sanofi to seek approval of touted eczema drug despite mixed results - BioPharma Dive
Sanofi to seek approval of touted eczema drug despite mixed results BioPharma Dive
What Sanofi’s multiple sclerosis troubles could mean for the space - BioPharma Dive
What Sanofi’s multiple sclerosis troubles could mean for the space BioPharma Dive
Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley - Fierce Pharma
Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley Fierce Pharma
Sanofi- Cell Research outstanding paper award of 2024 - Nature
Sanofi- Cell Research outstanding paper award of 2024 Nature
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal - Reuters
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal Reuters
Sanofi shares fall 6% after double setback for MS drug tolebrutinib - Clinical Trials Arena
Sanofi shares fall 6% after double setback for MS drug tolebrutinib Clinical Trials Arena
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales - BioSpace
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales BioSpace
Sanofi bids adieu to specialty care chief, promotes Manuela Buxo to assume key post - Fierce Pharma
Sanofi bids adieu to specialty care chief, promotes Manuela Buxo to assume key post Fierce Pharma
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Ga...
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Yahoo Finance
Sanofi Suffers Another Sales Dip for ‘Gift to Public Health’ Vaccines - BioSpace
Sanofi Suffers Another Sales Dip for ‘Gift to Public Health’ Vaccines BioSpace
Sanofi's vaccine ambitions unfazed by 'politics or sentiment in the now,' CEO Paul Hudson says - ...
Sanofi's vaccine ambitions unfazed by 'politics or sentiment in the now,' CEO Paul Hudson says Fierce Pharma
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi - Yahoo Finance
Press Release: Belén Garijo to become Chief Executive Officer of Sanofi Yahoo Finance
Is Sanofi (ENXTPA:SAN) Offering An Opportunity After A 19.5% One Year Share Price Fall - Yahoo Fi...
Is Sanofi (ENXTPA:SAN) Offering An Opportunity After A 19.5% One Year Share Price Fall Yahoo Finance
Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring - BioSpace
Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring BioSpace
Press Release: Sanofi completes the acquisition of Dynavax - Yahoo Finance
Press Release: Sanofi completes the acquisition of Dynavax Yahoo Finance
Sanofi sees near-term weakness in US vaccines sales due to antivax rhetoric - Reuters
Sanofi sees near-term weakness in US vaccines sales due to antivax rhetoric Reuters
Who is Sanofi's new CEO Belén Garijo? - Reuters
Sanofi’s stunning CEO switch—Chutes & Ladders - Fierce Biotech
Sanofi’s stunning CEO switch—Chutes & Ladders Fierce Biotech
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway - BioSpace
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway BioSpace
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials - BioPharma Dive
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials BioPharma Dive
Berenberg Bank Remains a Buy on Sanofi (SNY) - Yahoo Finance
Berenberg Bank Remains a Buy on Sanofi (SNY) Yahoo Finance
Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall - Reuters
Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall Reuters
Sanofi reopens courtship of eye disease biotech: report - FirstWord Pharma
Sanofi reopens courtship of eye disease biotech: report FirstWord Pharma
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease - Fierce ...
Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease Fierce Biotech
Kakao Healthcare, Sanofi partner to harness medical data for AI solutions - The Korea Times
Kakao Healthcare, Sanofi partner to harness medical data for AI solutions The Korea Times
Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant - CNBC
Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant CNBC
Is Sanofi Now an Opportunity After Recent Share Price Weakness? - Yahoo Finance
Is Sanofi Now an Opportunity After Recent Share Price Weakness? Yahoo Finance
Sanofi’s Dupixent successor heads to regulators after Phase III success - Clinical Trials Arena
Sanofi’s Dupixent successor heads to regulators after Phase III success Clinical Trials Arena
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite - CNBC
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite CNBC
Today at JPM: Sanofi on MFN misfires, cautious IPO optimism, pharma's AI embrace, and more… - Fir...
Today at JPM: Sanofi on MFN misfires, cautious IPO optimism, pharma's AI embrace, and more… FirstWord Pharma
Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... - Yahoo F...
Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... Yahoo Finance